Critical Care Management of DiabeticKetoacidosis Caused by Sodium-Glucose Co-Transporter 2 Inhibitor: A Case Report

References (5)

1. Chacko B, Whitley M, Beckmann U, Murray K, Rowley M. Postop-erative euglycaemic diabetic ketoacidosis associated with sodium-glu-cose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature. Anaesth Intensive Care 2018;46:215−9
2. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 2014;306:F188−93
3. FDA. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about. Ac-cessed March, 2020
4. D’Elia JA, Segal AR, Bayliss GP, Weinrauch LA. Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabe-tes: a review of US FDA data and possible conclusions. Int J Nephrol Renovasc Dis 2017;10:153−8
5. D’Elia JA, Segal AR, Weinrauch LA. Metformin-SGLT2, Dehydra-tion, and Acidosis Potential. J Am Geriatr Soc 2017;65:e101−e102.